Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database

Abstract

Statin use has been advocated to prevent atheromatous complications in lupus patients and may be widely prescribed for these patients in future. Statin-induced lupus has also been described, though the risk is not confirmed. The goal of this study was to detect a safety signal regarding statin-induced lupus. We conducted a case/non-case study in the French PharmacoVigilance Database from January 2000 until December 2010. Cases were drug-induced lupus reports. Non-cases were all reports of other adverse drug reactions (ADRs). Exposure to statins at the time of ADR was screened in each report. Among 235,147 ADR reports, 232 were drug-induced lupus. Exposure to statins was present in 17 (7.3%) cases and in 10,601 (4.7%) non-cases. Reporting odds ratio (ROR) for statin exposure associated with lupus erythematosus was 1.67 (95% confidence interval 1.02–2.74). The ROR was > 1 for each statin but fluvastatin. This pharmacoepidemiological study suggests a link between statin exposure and lupus induction. The benefit-to-risk ratio of statin therapy in lupus patients should be evaluated through randomized controlled trials.

Keywords

Statin lupus pharmacovigilance pharmacoepidemiology

Get full access to this article

View all access options for this article.

References

Chalubinski

Broncel

. Influence of statins on effector and regulatory immune mechanisms and their potential clinical relevance in treating autoimmune disorders. Med Sci Monit 2010; 16: RA245–RA251.

Van Leuven

Mendez-Fernandez

Stroes

Tak

Major

. Statin therapy in lupus-mediated atherogenesis: Two birds with one stone? Ann Rheum Dis 2011; 70: 245–248.

Plazak

Gryga

Dziedzic

. Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: A prospective, randomized, double-masked, placebo-controlled study. Arthritis Res Ther 2011; 13: R117–R117.

Petri

Kiani

Post

. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011; 70: 760–765.

Noël

Panizzon

. Lupus-like syndrome associated with statin therapy. Dermatology 2004; 208: 276–277.

Noël

. Lupus erythematosus and other autoimmune diseases related to statin therapy: A systematic review. J Eur Acad Dermatol Venereol 2007; 21: 17–24.

Montastruc

Sommet

Lacroix

. Pharmacovigilance for evaluating adverse drug reactions: Value, organization, and methods. Joint Bone Spine 2006; 73: 629–632.

Edwards

Aronson

. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255–1259.

Brown

Wood

. The medical dictionary for regulatory activities (MedDRA). Drug Saf 2009; 20: 109–117.

10.

WHO Collaborating Center for Drug Statistics Methodology. ATC / DDD index 2011. http://www.whocc.no/atc_ddd_index (2011, accessed 1 August 2011).

11.

Montastruc

Sommet

Bagheri

. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 2011; 72: 905–908.

12.

Marzano

Lazzari

Polloni

. Drug-induced subacute cutaneous lupus erythematosus: Evidence for differences from its idiopathic counterpart. Br J Dermatol 2011; 165: 335–341.

13.

De Jong HJ, Cohen Tervaert JW, Saldi SR, et al. Association between statin use and lupus-like syndrome using spontaneous reports. Semin Arthritis Rheum 2011; 41: 373–381.

14.

Lindquist

. VigiBase, the WHO Global ICSR Database System: Basic facts. Drug Inform J 2008; 42: 409–419.

15.

Sailler

Pereira

Bagheri

. Increased exposure to statins in patients developing chronic muscle diseases: A 2-year retrospective study. Ann Rheum Dis 2008; 67: 614–619.